Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials
Open Access
- 6 September 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 33 (4) , 430-432
- https://doi.org/10.1093/eurheartj/ehr310
Abstract
This editorial refers to ‘Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial’†, by P.S. Sever et al., on page 486Keywords
This publication has 17 references indexed in Scilit:
- C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysisThe Lancet, 2009
- C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart StudyCirculation: Cardiovascular Quality and Outcomes, 2008
- C-Reactive Protein Levels and Outcomes after Statin TherapyNew England Journal of Medicine, 2005
- Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary SyndromesNew England Journal of Medicine, 2004
- C-Reactive Protein Modulates Risk Prediction Based on the Framingham ScoreCirculation, 2004
- Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary EventsNew England Journal of Medicine, 2001
- Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol LevelsCirculation, 1998
- Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy MenNew England Journal of Medicine, 1997
- The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable AnginaNew England Journal of Medicine, 1994